Top Story

Amino acid peptide improves signs, symptoms in severe dry eye

May 22, 2015

Patients with chronic graft-vs.-host disease who were treated with thymosin β4 eye drops (RGN-259, 0.1%) experienced statistically significant improvements in signs and symptoms, according to a study published in Cornea.

Sosne and colleagues conducted a randomized, double-masked, placebo-controlled phase 2 clinical trial at two U.S. sites. Researchers treated nine men and women older than 18 years with severe dry eye with either Tβ4, a naturally occurring 43 amino acid peptide found in high concentrations in most tissues and cells, or placebo six times a day. The 56-day trial included a 28-day follow-up.

NEI commits to develop noninvasive imaging technology

May 25, 2015
The National Eye Instituted announced that it will provide $3.8 million in 2015 and up to $17.9 million over the next 5 years to support five projects involving new…
VIDEO: Combination therapy better manages postop inflammation Meeting News CoverageVideo

VIDEO: Combination therapy better manages postop inflammation

May 25, 2015
MILAN — At the OSN Italy meeting, Luigi Fontana, MD, talks about postoperative management of inflammation after cataract surgery. In a single center randomized clinical…
Business News

Spark Therapeutics reports $2.3 million in revenue in first quarter

May 25, 2015
Spark Therapeutics, developer of SPK-RPE65, a potential gene therapy treatment for RPE65-mediated inherited retinal degenerations, reported $2.3 million in revenue in…
VIDEO: Update on microinvasive glaucoma procedures Meeting News CoverageVideo

VIDEO: Update on microinvasive glaucoma procedures

May 24, 2015
MILAN — At the OSN Italy meeting, E. Randy Craven, MD, talks about microinvasive glaucoma procedures, specifically focusing on microstents and the option of using two…
More News Headlines »
Video
Agustin Gonzalez

BLOG: Keep your enemies close

April 28, 2015
Agustin L. Gonzalez, OD, FAAO, reminds us of the adage: “Keep your friends close, but your enemies…
More »